{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,14]],"date-time":"2026-11-14T02:15:04Z","timestamp":1794622504739,"version":"4.9.1"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,9,21]],"date-time":"2020-09-21T00:00:00Z","timestamp":1600646400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,9,21]],"date-time":"2020-09-21T00:00:00Z","timestamp":1600646400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100006259","name":"Teva Pharmaceutical Industries","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006259","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Headache Pain"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n<jats:title>Background<\/jats:title>\n<jats:p>We evaluated the efficacy of fremanezumab, a fully humanized monoclonal antibody that selectively targets calcitonin gene-related peptide, in patients with chronic migraine (CM) with and without medication overuse (MO).<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Methods<\/jats:title>\n<jats:p>In a 12-week, phase 3 trial, patients with CM were randomized to fremanezumab quarterly (675\u2009mg\/placebo\/placebo), monthly (675\u2009mg\/225\u2009mg\/225\u2009mg), or placebo. Post hoc analyses assessed the impact of fremanezumab in patients with and without MO (monthly use of acute headache medication \u226515\u2009days, migraine-specific acute medication \u226510\u2009days, or combination medication \u226510\u2009days) on efficacy outcomes, including headache days of at least moderate severity (HDs), and six-item Headache Impact Test (HIT-6) and Migraine-Specific Quality of Life (MSQoL) questionnaire scores.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Results<\/jats:title>\n<jats:p>Of 1130 patients enrolled, 587 (51.9%) had baseline MO. Fremanezumab reduced placebo-adjusted least-squares mean (95% confidence interval) monthly HDs (\u2212\u20092.2 [\u2212\u20093.1 to \u2212\u20091.2] and\u2009\u2212\u20092.7 [\u2212\u20093.7 to \u2212\u20091.8]; <jats:italic>P<\/jats:italic>\u2009&lt;\u20090.0001) in patients with MO and without MO (quarterly \u2212\u20091.4 [\u2212\u20092.3 to \u2212\u20090.5], <jats:italic>P<\/jats:italic>\u2009=\u20090.0026; monthly \u2212\u20091.4 [\u2212\u20092.3 to \u2212\u20090.6], <jats:italic>P<\/jats:italic>\u2009=\u20090.0017). Significantly more fremanezumab-treated patients had \u2265 50% reduction in HDs versus placebo, regardless of baseline MO (with: quarterly 70\/201 [34.8%], monthly 78\/198 [39.4%] vs placebo 26\/188 [13.8%]; without: quarterly 71\/174 [40.8%], monthly 75\/177 [42.4%] vs placebo 41\/183 [22.4%]). Fremanezumab improved HIT-6 and MSQoL scores. Significantly more fremanezumab-treated patients reverted to no MO (quarterly 111\/201 [55.2%], monthly 120\/198 [60.6%]) versus placebo (87\/188 [46.3%]).<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Conclusions<\/jats:title>\n<jats:p>Fremanezumab is effective for prevention of migraine in patients with CM, regardless of MO, and demonstrated a benefit over placebo in reducing MO.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Trial registration<\/jats:title>\n<jats:p>ClinicalTrials.gov <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02621931\">NCT02621931<\/jats:ext-link> (HALO CM), registered December 12, 2012.<\/jats:p>\n<\/jats:sec>","DOI":"10.1186\/s10194-020-01173-8","type":"journal-article","created":{"date-parts":[[2020,9,21]],"date-time":"2020-09-21T18:03:22Z","timestamp":1600711402000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":120,"title":["The impact of fremanezumab on medication overuse in patients with chronic migraine: subgroup analysis of the HALO CM study"],"prefix":"10.1186","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9467-5567","authenticated-orcid":false,"given":"Stephen D.","family":"Silberstein","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua M.","family":"Cohen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael J.","family":"Seminerio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronghua","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sait","family":"Ashina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zaza","family":"Katsarava","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,9,21]]},"reference":[{"key":"1173_CR1","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1177\/0333102411398400","volume":"31","author":"M Lanteri-Minet","year":"2011","unstructured":"Lanteri-Minet M, Duru G, Mudge M, Cottrell S (2011) Quality of life impairment, disability and economic burden associated with chronic daily headache, focusing on chronic migraine with or without medication overuse: a systematic review. Cephalalgia. 31:837\u2013850","journal-title":"Cephalalgia."},{"key":"1173_CR2","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1186\/s10194-018-0875-x","volume":"19","author":"N Vandenbussche","year":"2018","unstructured":"Vandenbussche N, Laterza D, Lisicki M, Lloyd J, Lupi C, Tischler H et al (2018) Medication-overuse headache: a widely recognized entity amidst ongoing debate. J Headache Pain. 19:50","journal-title":"J Headache Pain."},{"key":"1173_CR3","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1177\/2042098614522683","volume":"5","author":"ES Kristoffersen","year":"2014","unstructured":"Kristoffersen ES, Lundqvist C (2014) Medication-overuse headache: epidemiology, diagnosis and treatment. Ther Adv Drug Saf 5:87\u201399","journal-title":"Ther Adv Drug Saf"},{"key":"1173_CR4","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1212\/WNL.0000000000004112","volume":"89","author":"K Probyn","year":"2017","unstructured":"Probyn K, Bowers H, Caldwell F, Mistry D, Underwood M, Matharu M et al (2017) Prognostic factors for chronic headache: a systematic review. Neurology. 89:291\u2013301","journal-title":"Neurology."},{"key":"1173_CR5","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1111\/head.12223","volume":"54","author":"AN Da Silva","year":"2014","unstructured":"Da Silva AN, Lake AE 3rd. (2014) Clinical aspects of medication overuse headaches. Headache. 54:211\u2013217","journal-title":"Headache."},{"key":"1173_CR6","doi-asserted-by":"crossref","unstructured":"American Headache Society (2019) The American Headache Society position statement on integrating new migraine treatments into clinical practice. Headache. 59:1\u201318","DOI":"10.1111\/head.13496"},{"key":"1173_CR7","first-page":"973","volume":"21","author":"SD Silberstein","year":"2015","unstructured":"Silberstein SD (2015) Preventive migraine treatment. Continuum (Minneap Minn) 21:973\u2013989","journal-title":"Continuum (Minneap Minn)"},{"issue":"5","key":"1173_CR8","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1212\/01.wnl.0000252808.97649.21","volume":"68","author":"RB Lipton","year":"2007","unstructured":"Lipton RB, Bigal ME, Diamond M, Freitag F, Reed ML, Stewart WF et al (2007) Migraine prevalence, disease burden, and the need for preventive therapy. Neurology. 68(5):343\u2013349","journal-title":"Neurology."},{"key":"1173_CR9","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1186\/s10194-018-0839-1","volume":"19","author":"Z Katsarava","year":"2018","unstructured":"Katsarava Z, Mania M, Lampl C, Herberhold J, Steiner TJ (2018) Poor medical care for people with migraine in Europe - evidence from the Eurolight study. J Headache Pain 19:10","journal-title":"J Headache Pain"},{"key":"1173_CR10","doi-asserted-by":"crossref","unstructured":"Blumenfeld AM, Bloudek LM, Becker WJ, Buse DC, Varon SF, Maglinte GA et al (2013) Patterns of use and reasons for discontinuation of prophylactic medications for episodic migraine and chronic migraine: results from the second International Burden of Migraine Study (IBMS-II). Headache. 53:644\u2013655","DOI":"10.1111\/head.12055"},{"key":"1173_CR11","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1177\/0333102416678382","volume":"37","author":"Z Hepp","year":"2017","unstructured":"Hepp Z, Dodick DW, Varon SF, Chia J, Matthew N, Gillard P et al (2017) Persistence and switching patterns of oral migraine prophylactic medications among patients with chronic migraine: a retrospective claims analysis. Cephalalgia. 37:470\u2013485","journal-title":"Cephalalgia."},{"key":"1173_CR12","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1007\/s13311-018-0626-3","volume":"15","author":"PJ Goadsby","year":"2018","unstructured":"Goadsby PJ, Holland PR (2018) Migraine therapy: current approaches and new horizons. Neurotherapeutics. 15:271\u2013273","journal-title":"Neurotherapeutics."},{"key":"1173_CR13","doi-asserted-by":"crossref","first-page":"22","DOI":"10.18553\/jmcp.2014.20.1.22","volume":"20","author":"Z Hepp","year":"2014","unstructured":"Hepp Z, Bloudek LM, Varon SF (2014) Systematic review of migraine prophylaxis adherence and persistence. J Manag Care Pharm 20:22\u201333","journal-title":"J Manag Care Pharm"},{"key":"1173_CR14","unstructured":"AJOVY\u00ae (fremanezumab) [prescribing information]. Teva Pharmaceuticals USA, Inc.; 2020. https:\/\/www.ajovyhcp.com\/globalassets\/ajovy\/ajovy-pi.pdf. Accessed 25 Aug 2020."},{"key":"1173_CR15","unstructured":"AJOVY (fremanezumab) [Summary of Product Characteristics]. Teva Pharmaceuticals GmbH; 2019. https:\/\/data.health.gov.il\/drugs\/alonim\/Rishum_12_563143019.pdf. Accessed 25 Aug 2020."},{"key":"1173_CR16","doi-asserted-by":"publisher","first-page":"2113","DOI":"10.1056\/NEJMoa1709038","volume":"377","author":"SD Silberstein","year":"2017","unstructured":"Silberstein SD, Dodick DW, Bigal ME, Yeung PP, Goadsby PJ, Blankenbiller T et al (2017) Fremanezumab for the preventive treatment of chronic migraine. N Engl J Med 377:2113\u20132122","journal-title":"N Engl J Med"},{"key":"1173_CR17","doi-asserted-by":"crossref","unstructured":"Headache Classification Committee of the International Headache Society (2013) The International Classification of Headache Disorders, 3rd edition (beta version). Cephalalgia. 33(9):629\u2013808","DOI":"10.1177\/0333102413485658"},{"key":"1173_CR18","doi-asserted-by":"crossref","unstructured":"Yang M, Rendas-Baum R, Varon SF, Kosinski M (2011) Validation of the Headache Impact Test (HIT-6\u2122) across episodic and chronic migraine. Cephalalgia. 31:357\u2013367","DOI":"10.1177\/0333102410379890"},{"key":"1173_CR19","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1111\/j.1526-4610.2011.01997.x","volume":"52","author":"CL Bagley","year":"2012","unstructured":"Bagley CL, Rendas-Baum R, Maglinte GA, Yang M, Varon SF, Lee J et al (2012) Validating migraine-specific quality of life questionnaire v2.1 in episodic and chronic migraine. Headache. 52:409\u2013421","journal-title":"Headache."},{"key":"1173_CR20","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1046\/j.1525-1497.2001.016009606.x","volume":"16","author":"K Kroenke","year":"2001","unstructured":"Kroenke K, Spitzer RL, Williams JB (2001) The PHQ-9: validity of a brief depression severity measure. J Gen Intern Med 16:606\u2013613","journal-title":"J Gen Intern Med"},{"issue":"10","key":"1173_CR21","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1111\/j.1468-2982.2009.01859.x","volume":"29","author":"H Diener","year":"2009","unstructured":"Diener H, Dodick DW, Goadsby P, Bigal M, Bussone G, Silberstein S et al (2009) Utility of topiramate for the treatment of patients with chronic migraine in the presence or absence of acute medication overuse. Cephalalgia. 29(10):1021\u20131027","journal-title":"Cephalalgia."},{"issue":"10","key":"1173_CR22","doi-asserted-by":"publisher","first-page":"1192","DOI":"10.1111\/j.1468-2982.2006.01190.x","volume":"26","author":"P Zeeberg","year":"2006","unstructured":"Zeeberg P, Olesen J, Jensen R (2006) Discontinuation of medication overuse in headache patients: recovery of therapeutic responsiveness. Cephalalgia. 26(10):1192\u20131198","journal-title":"Cephalalgia."},{"key":"1173_CR23","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1136\/jnnp.2009.192492","volume":"81","author":"DC Buse","year":"2010","unstructured":"Buse DC, Manack A, Serrano D, Turkel C, Lipton RB (2010) Sociodemographic and comorbidity profiles of chronic migraine and episodic migraine sufferers. J Neurol Neurosurg Psychiatry 81:428\u2013432","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"1173_CR24","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1038\/nrneurol.2016.124","volume":"12","author":"HC Diener","year":"2016","unstructured":"Diener HC, Holle D, Solbach K, Gaul C (2016) Medication-overuse headache: risk factors, pathophysiology and management. Nat Rev Neurol 12:575\u2013583","journal-title":"Nat Rev Neurol"},{"key":"1173_CR25","doi-asserted-by":"publisher","first-page":"1162","DOI":"10.1002\/ejp.1383","volume":"23","author":"IMS Engelstoft","year":"2019","unstructured":"Engelstoft IMS, Carlsen LN, Munksgaard SB, Nielsen M, Jensen RH, Bendtsen L (2019) Complete withdrawal is the most feasible treatment for medication-overuse headache: a randomized controlled open-label trial. Eur J Pain 23:1162\u20131170","journal-title":"Eur J Pain"},{"key":"1173_CR26","doi-asserted-by":"publisher","first-page":"e8493","DOI":"10.1097\/MD.0000000000008493","volume":"96","author":"T Benz","year":"2017","unstructured":"Benz T, N\u00fcssle A, Lehmann S, Gantenbein AR, S\u00e1ndor PS, Elfering A et al (2017) Health and quality of life in patients with medication overuse headache syndrome after standardized inpatient rehabilitation: a cross-sectional pilot study. Medicine. 96:e8493","journal-title":"Medicine."},{"key":"1173_CR27","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1111\/j.1468-1331.2011.03497.x","volume":"18","author":"S Evers","year":"2011","unstructured":"Evers S, Jensen R (2011) Treatment of medication overuse headache\u2013guideline of the EFNS headache panel. Eur J Neurol 18:1115\u20131121","journal-title":"Eur J Neurol"},{"key":"1173_CR28","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1177\/0333102415593088","volume":"36","author":"C-C Chiang","year":"2016","unstructured":"Chiang C-C, Schwedt TJ, Wang S-J, Dodick DW (2016) Treatment of medication-overuse headache: a systematic review. Cephalalgia. 36:371\u2013386","journal-title":"Cephalalgia."},{"key":"1173_CR29","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1111\/head.12224","volume":"54","author":"A Srikiatkhachorn","year":"2014","unstructured":"Srikiatkhachorn A, le Grand SM, Supornsilpchai W, Storer RJ (2014) Pathophysiology of medication overuse headache--an update. Headache. 54:204\u2013210","journal-title":"Headache."},{"key":"1173_CR30","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1016\/S1474-4422(19)30146-2","volume":"18","author":"HC Diener","year":"2019","unstructured":"Diener HC, Dodick D, Evers S, Holle D, Jensen RH, Lipton RB et al (2019) Pathophysiology, prevention, and treatment of medication overuse headache. Lancet Neurol 18:891\u2013902","journal-title":"Lancet Neurol"},{"key":"1173_CR31","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1177\/0333102416650702","volume":"37","author":"CM Kopruszinski","year":"2017","unstructured":"Kopruszinski CM, Xie JY, Eyde NM, Remeniuk B, Walter S, Stratton J et al (2017) Prevention of stress- or nitric oxide donor-induced medication overuse headache by a calcitonin gene-related peptide antibody in rodents. Cephalalgia. 37:560\u2013570","journal-title":"Cephalalgia."}],"container-title":["The Journal of Headache and Pain"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s10194-020-01173-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s10194-020-01173-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s10194-020-01173-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,20]],"date-time":"2021-09-20T23:09:51Z","timestamp":1632179391000},"score":1,"resource":{"primary":{"URL":"https:\/\/thejournalofheadacheandpain.biomedcentral.com\/articles\/10.1186\/s10194-020-01173-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9,21]]},"references-count":31,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["1173"],"URL":"https:\/\/doi.org\/10.1186\/s10194-020-01173-8","relation":{},"ISSN":["1129-2369","1129-2377"],"issn-type":[{"value":"1129-2369","type":"print"},{"value":"1129-2377","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,9,21]]},"assertion":[{"value":"22 June 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 August 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 September 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"As part of the original study, all patients provided written informed consent and the trial was approved by all relevant review bodies. Because the subgroup analyses used existing data from the primary study, additional consent was not required.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"SDS provides consultation to Abide Therapeutics, Allergan, Amgen, Avanir, Biohaven, Cefaly, Curelator, Inc., Dr. Reddy\u2019s Laboratories, Egalet Corporation, GlaxoSmithKline Consumer Health Holdings, LLC, eNeura Inc., electroCore Medical, LLC, Impel NeuroPharma, Inc., Lilly USA, LLC, Medscape, LLC, Novartis, Inc., Satsuma Pharmaceuticals, Supernus Pharmaceuticals, Inc., Teva Pharmaceuticals, Theranica, and Trigemina, Inc. JMC, MJS, and RY are employees of Teva Branded Pharmaceutical Products R&D, Inc. (USA). SA provides consultation for Allergan, Amgen, Promius, Supernus, and Novartis. ZK provides consultation to Allergan, Novartis, Eli Lilly, and Teva Pharmaceuticals.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"114"}}